High resolution chromosomal microarray in undiagnosed neurological disorders. Issue 9 (3rd June 2013)

• Record Type: Journal Article
• Authors: Howell, Katherine B; Kornberg, Andrew J; Harvey, A Simon; Ryan, Monique M; Mackay, Mark T; Freeman, Jeremy L; Rodriguez Casero, M Victoria; Collins, Kevin J; Hayman, Michael; Mohamed, Ahmad; Ware, Tyson L; Clark, Damian; Bruno, Damien L; Burgess, Trent; Slater, Howard; McGillivray, George; Leventer, Richard J
• Is Part Of: Journal of paediatrics and child health. Volume 49:Issue 9(2013:Sep.)
• Page Start: 716
• Page End: 724
• Publication Date: 2013-06-03
• Subjects: chromosomal microarray -- copy number variant -- long continuous stretch homozygosity -- single nucleotide polymorphism microarray.; Children -- Health and hygiene -- Periodicals; Pediatrics -- Periodicals; 618.92
• DOI: 10.1111/jpc.12256
• Languages: English
• ISSNs: 1034-4810

Abstract

Abstract : Aim: Despite advances in medical investigation, many children with neurological conditions remain without a diagnosis, although a genetic aetiology is often suspected. Chromosomal microarray (CMA) screens for copy number variants (CNVs) and long continuous stretches of homozygosity (LCSH) and may further enhance diagnostic yield. Although recent studies have identified pathogenic CNVs in intellectual disability, autism and epilepsy, the utility of CMA testing in a broader cohort of children with neurologic disorders has not been reported. Methods: Two hundred fifteen patients with neurological conditions of unknown aetiology were seen over a 6‐month period and were prospectively tested by CMA using high‐resolution single nucleotide polymorphism (SNP) microarrays (Illumina HumanCytoSNP‐12 v2.1 or Affymetrix 2.7M). Results: Thirty of 215 (14%) patients tested had an abnormal CMA. Twenty‐nine had CNVs (13%) and one (0.5%) a clinically significant stretch of homozygosity. Twenty (9.3%) had a CMA finding considered to be pathogenic or involved in susceptibility to the condition of interest, and 10 (4.7%) had findings of unknown significance. Their phenotypes included infantile spasms and other epilepsies, neuromuscular conditions, ataxia, movement disorders, microcephaly and malformations of cortical development. At least one third of patients did not meet national funding criteria for CMA at the time of presentation. Conclusions: CMA detected clinically significant abnormalities in a broad range of neurologic phenotypes of unknown aetiology. This test should be considered a first‐tier investigation of children with neurologic disorders in whom the initial clinical assessment does not indicate a likely aetiology, especially those with severe epilepsies and neurologically abnormal neonates.